Jonas Vingegaard and his participation in the Cycling World Championships are hot topics of conversation in the Danish ...

With looks to kill – and tuning and intonation that promises to withstand even the most aggressive of play styles – Cort’s ...

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Highlights,Corcept Therapeutics (CORT) shares increased by 5.5% in the latest trading session, closing at $49.75, driven by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Corcept Therapeutics Inc (CORT) reports a 48% revenue increase and raises 2024 guidance, while navigating ongoing litigation and clinical challenges.

Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter. As the U.S. stock market experiences a surge, led by a rally in the ...

Vandana Singh Corcept Moves 6.5% Higher: Will This Strength Last? Corcept Therapeutics (NASDAQ: CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by ...

Shares of Corcept Therapeutics (CORT) have gained 11.8% over the past four weeks to close the last trading session at $47.27, but there could still be a solid upside left in the stock if short ...

Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like cancer and ALS. Corcept's academic alliances enhance its ...